CD Genomics Unveils Cutting-Edge DNA 6mA Sequencing Service for Epigenomic Research

CD Genomics, a renowned provider of genomics and epigenomics solutions, is pleased to announce the launch of its state-of-the-art DNA 6mA Sequencing service. This revolutionary technology promises to open new avenues in epigenetic research, offering scientists unprecedented insights into DNA methylation dynamics.


Epigenetics, the study of heritable changes in gene function that do not entail changes to the underlying DNA sequence, plays a pivotal role in various biological processes, including development, disease, and evolution. Among the epigenetic modifications, DNA methylation at the N6 position of adenine (6mA) has garnered substantial attention for its potential to regulate gene expression and cellular functions.


With CD Genomics' DNA 6mA Sequencing service, researchers now have access to an opportunity to explore the 6mA epigenome with unparalleled precision, sensitivity, and cost-efficiency. Here's why this service stands out:


1. Cutting-Edge Technology: CD Genomics' DNA 6mA Sequencing capitalizes on the latest advancements in high-throughput sequencing platforms, ensuring accurate and comprehensive 6mA profiling across the entire genome.


2. Robust Bioinformatics Analysis: The CD Genomics team of bioinformatics experts provides in-depth data analysis, yielding valuable insights into 6mA distribution, differential methylation, and functional annotations.


3. Customized Solutions: CD Genomics offers flexible service options tailored to specific research needs, from sample preparation to data analysis. Whether one requires genome-wide mapping or targeted region analysis, CD Genomics has it covered.


4. High-Quality Data: At CD Genomics, quality is paramount. Rigorous quality control measures guarantee reliable and reproducible results for epigenomic studies.


5. Rapid Turnaround Time: CD Genomics understands the significance of time in research. Efficient workflows ensure a quick turnaround, empowering researchers to expedite their discoveries.


6mA DNA methylation is implicated in gene regulation and plays a pivotal role in diverse biological processes, including bacterial defence systems and viral infections. Understanding the intricacies of 6mA methylation can have far-reaching implications in fields such as microbiology, immunology, and cancer research.


In addition to the DNA 6mA Sequencing service, CD Genomics offers a comprehensive suite of epigenomic solutions, including ChIP-Seq, DNA Methylation Analysis, and RNA-Seq. These services can be seamlessly integrated into researchers' workflows to provide a holistic view of epigenetic regulation.


Senior Scientist at CD Genomics expressed his enthusiasm for launching the DNA 6mA Sequencing service, stating, "We are committed to supporting the global scientific community in advancing epigenomic research. Our new DNA 6mA Sequencing service exemplifies our dedication to innovation and excellence."


With the introduction of this cutting-edge technology, CD Genomics continues to lead in genomics and epigenomics, empowering researchers worldwide to unravel the mysteries of epigenetic regulation and its impact on health and disease.


About CD Genomics

CD Genomics is a leading genomics and epigenomics service provider, dedicated to delivering high-quality sequencing and data analysis solutions to researchers worldwide. With state-of-the-art facilities and a team of experienced scientists, CD Genomics is committed to advancing genomics and epigenomics research across diverse fields.



Address: Shirley, NY 11967, USA